Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD - PubMed (original) (raw)
Clinical Trial
Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD
Howard Abikoff et al. J Am Acad Child Adolesc Psychiatry. 2009 Feb.
Abstract
Objective: To evaluate the effects of stimulant medication on organizational, time management, and planning (OTMP) in children with attention-deficit/hyperactivity disorder (ADHD) and ascertain whether OTMP is normalized with medication.
Method: Participants included 19 stimulant-naïve children with ADHD (aged 8-13 years) and impaired OTMP functioning, defined as greater than 1 SD below norms on the Children's Organizational Skills Scale. A double-blind, placebo-controlled, crossover design, with 4 weeks of each condition, evaluated medication (methylphenidate-osmotic-release oral system [MPH-OROS]) effects on OTMP, based on the parent and teacher versions of the Children's Organizational Skills Scale. The parent and teacher Swanson, Nolan, and Pelham, Version IV, rating scales assessed ADHD symptoms. "Not impaired" in OTMP was defined as no longer meeting study entry criteria, and "not impaired" in ADHD symptoms was defined as having mean Swanson, Nolan, and Pelham, Version IV, scores of < or = 1.0.
Results: MPH-OROS significantly improved children's OTMP behaviors. These improvements were correlated with significant reductions in ADHD symptoms. However, most of the children (61%) continued to show significant OTMP impairments on MPH-OROS.
Conclusions: The MPH-OROS reduced children's OTMP deficits, and these improvements were associated with improvements in ADHD symptoms. Some children remained impaired in OTMP even after effective stimulant treatment of ADHD symptoms. These youngsters may require other treatments that target OTMP deficits.
Similar articles
- Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H. Chou WJ, et al. Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x. Psychiatry Clin Neurosci. 2009. PMID: 19335386 Clinical Trial. - A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. Wigal S, et al. J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14. doi: 10.1097/01.chi.0000138351.98604.92. J Am Acad Child Adolesc Psychiatry. 2004. PMID: 15502600 Clinical Trial. - Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B. Kordon A, et al. Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457. Postgrad Med. 2011. PMID: 21904084 Clinical Trial. - OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. Ramos-Quiroga JA, et al. Expert Rev Neurother. 2009 Aug;9(8):1121-31. doi: 10.1586/ern.09.65. Expert Rev Neurother. 2009. PMID: 19673602 Review. - Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL. Findling RL. Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Clin Ther. 2008. PMID: 18555941 Review.
Cited by
- Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.
Mizuno K, Yoneda T, Komi M, Hirai T, Watanabe Y, Tomoda A. Mizuno K, et al. Neuroimage Clin. 2013 Mar 16;2:366-76. doi: 10.1016/j.nicl.2013.03.004. eCollection 2013. Neuroimage Clin. 2013. PMID: 24179790 Free PMC article. - Dismantling cognitive-behavioural therapy components for attention-deficit hyperactivity disorder in adolescents and adults: protocol for a network meta-analysis.
Hamatani S, Matsumoto K, Kunisato Y, Okawa S, Yamashita M, Mizuno Y. Hamatani S, et al. BMJ Open. 2023 Apr 19;13(4):e068547. doi: 10.1136/bmjopen-2022-068547. BMJ Open. 2023. PMID: 37076162 Free PMC article. - Impact of stimulant medication on behaviour and executive functions in children with attention-deficit/hyperactivity disorder.
Hai T, Duffy HA, Lemay JA, Lemay JF. Hai T, et al. World J Clin Pediatr. 2022 Jan 9;11(1):48-60. doi: 10.5409/wjcp.v11.i1.48. eCollection 2022 Jan 9. World J Clin Pediatr. 2022. PMID: 35096546 Free PMC article. - The effect of methylphenidate-OROS® on the narrative ability of children with attention-deficit hyperactivity disorder.
Rausch TL, Kendall DL, Kover ST, Louw EM, Zsilavecz UL, Van der Merwe A. Rausch TL, et al. S Afr J Commun Disord. 2017 Feb 27;64(1):e1-e12. doi: 10.4102/sajcd.v64i1.180. S Afr J Commun Disord. 2017. PMID: 28281767 Free PMC article. - Evaluation of the Homework, Organization, and Planning Skills (HOPS) Intervention for Middle School Students with ADHD as Implemented by School Mental Health Providers.
Langberg JM, Epstein JN, Becker SP, Girio-Herrera E, Vaughn AJ. Langberg JM, et al. School Psych Rev. 2012 Sep;41(3):342-364. School Psych Rev. 2012. PMID: 25355991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical